Engraftment syndrome (ES) is an increasingly reported complication of hematopoietic stem cell transplantation (HSCT). In order to better characterize the clinical criteria for the diagnosis of ES, we retrospectively analyzed 125 autologous HSCT recipients. ES was first defined as the presence of noninfectious fever plus skin rash. Patients with and without these findings were compared (univariate and multivariate analyses) regarding the presence of weight gain, hypoalbuminemia, pulmonary infiltrates, diarrhea, neurological manifestations and jaundice. The variables that are significantly more frequent in patients with fever and skin rash were incorporated in the definition criteria. The final diagnostic criteria were noninfectious fever plus any of the following: skin rash, pulmonary infiltrates or diarrhea. The incidence of ES was 20%. The single risk factor for ES by multivariate analysis was a diagnosis other than Hodgkin's disease (odds ratio 6.17, 95% confidence interval 1.38-27.78). Patients with ES received empirical antifungal therapy more frequently than patients without the syndrome (40 vs 19%, P ¼ 0.03), and had a longer duration of hospitalization (P ¼ 0.0007). The prospective application of these diagnostic criteria may have a favorable impact on the early diagnosis of the syndrome, with the initiation of corticosteroids and a reduction in the unnecessary use of antimicrobial agents.
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Engraftment syndrome (ES) is a febrile syndrome that occurs in the early neutrophil recovery phase following hematopoietic stem cell transplantation (HSCT). 1 It is characterized by noninfectious fever and various clinical findings, such as skin rash mimicking acute graft-versushost disease, diarrhea, pulmonary infiltrates, weight gain and neurological manifestations. The pathogenesis of the ES is not clearly understood, but involves the release of proinflammatory cytokines, including interleukin-1 and tumor necrosis factor-a. 2 Although the ES has been described after allogeneic HSCT, 3 it occurs more frequently in autologous HSCT.
Since there is no uniform definition, reports of the incidence and risk factors for the ES have varied widely among different publications. An incidence of 7-9% has been reported by authors who used stringent definitions, 4, 5 whereas in studies that used wider definitions, the incidence was as high as 59%. 6 Likewise, different risk factors have been identified, including the underlying disease, 4 type of chemotherapeutic agent used in the conditioning regimen, 2 ,5 the number of cycles of previous chemotherapy, 7 previous radiotherapy, 2 number of cells infused and faster engraftment. 4, 5 Therefore, much of the data regarding clinical and epidemiological aspects of the ES are hampered by the lack of a uniform definition for the syndrome.
In this study, we evaluated clinical data of 125 autologous HSCT recipients in order to better characterize the clinical criteria for the diagnosis of the ES.
Patients and methods

Patients
The charts of 125 consecutive autologous HSCT recipients treated between June 1994 and September 2000 at the University Hospital, Universidade Federal do Rio de Janeiro, Brazil, were reviewed. There were 63 males and 62 females, with a median age of 43 years (range 8-65). Multiple myeloma was the most frequent underlying disease (45 patients), followed by Hodgkin's disease (37 patients), non-Hodgkin's lymphoma (29 patients), breast cancer (six patients), acute myeloid leukemia (five patients), and germ cell tumor, plasma cell leukemia and amyloidosis (one patient each). The source of stem cells was the bone marrow in 23 patients and the peripheral blood in 102 patients. Cyclophosphamide followed by granulocyte colony-stimulating factor (G-CSF) was used for peripheral blood progenitor cells mobilization. G-CSF was not used before bone marrow collection. The conditioning regimen for patients with non-Hodgkin's lymphoma and Hodgkin's disease was CBV (cyclophosphamide 6 g/m 2 ). G-CSF was started on day +1 in all patients until June 1997, and on day +5 between July 1997 and May 1998, when a randomized study comparing two schedules of initiation of G-CSF was started. 8 Overall, 51 patients received G-CSF on day +1 and the remaining 74 patients received G-CSF on day +5. All patients received acyclovir for prophylaxis of herpes simplex, and only the first 28 patients received antibacterial prophylaxis (ciprofloxacin). Until July 1997, antifungal prophylaxis was given according to a randomized trial that compared itraconazol and placebo, 9 and after that, all patients received fluconazole. The patients were admitted to single rooms without HEPA filters or laminar airflow. Patients with fever were submitted to a comprehensive workup for infection that included history, physical examination and two sets of blood cultures. Cultures of other sites, biopsies and radiological examinations were performed when clinically indicated. Until 1998, empirical antibiotic therapy consisted of ceftazidime plus amikacin, with vancomycin being added empirically to persistently febrile patients. From January 1998, cefepime was given as empirical therapy, and vancomycin was given only in special situations. 10 Amphotericin B was started empirically after 6 days of persistent fever, or with a new fever in patients who had become afebrile, provided that no signs of bone marrow recovery were present.
Definition of the ES
In order to characterize the ES, we first used a stringent criterion of the ES: noninfectious fever plus skin rash mimicking acute graft-versus-host disease. Patients with and without these findings were compared regarding the presence of other clinical findings used as criteria in other studies: weight gain, hypoalbuminemia, pulmonary infiltrates, diarrhea, neurological manifestations and jaundice. The variables that were significantly more frequent in patients with fever and skin rash were entered in a logistic regression analysis, and those that remained significant were incorporated in our definition criteria for the ES. All clinical signs had to have started 24 h before or after the first appearance of neutrophils in the peripheral blood. Clinical manifestations suggestive of the ES that occurred in patients with any clinical or microbiological documentation of infection occurring 2 days before or after the first appearance of these manifestations were not attributed to the ES.
In order to assess risk factors for the ES, we compared patients with and without the syndrome regarding gender, age, underlying disease, previous chemotherapy and radiotherapy, source of stem cells, number of mononuclear and CD34+ cells infused, timing of G-CSF initiation and time to engraftment. Variables with P-values o0.1 were entered in a multivariate logistic regression analysis.
Noninfectious fever was defined as a new fever (4381C) without clinical or microbiological documentation of infection, or response to antimicrobial agents. Pulmonary infiltrates were documented by chest X-ray or computed tomography, and were considered to be part of the ES if there were no signs of cardiac failure, pulmonary embolism or infection. Weight gain was defined as a 3% increase in body weight from day zero of transplant. Skin rash was defined as the appearance of a diffuse maculo-papular exanthema mimicking acute graft-versus-host disease, without evidence of infection. A biopsy demonstrating histologic changes consistent with a diagnosis of autologous graft-versus-host disease was not required. Noninfectious diarrhea was defined as at least two episodes of liquid bowel movements per day without documentation of infection by standard procedures. Response to empirical antibiotic therapy was defined according to standard definitions. 11 To compare dichotomous variables, Fisher (two-tailed) and w 2 tests were performed, and to compare continuous variables, the Wilcoxon test was used. Multivariate analysis was performed by forward and backward procedures. Registration and analysis of data were done using Epi-Info 6.04 software (Centers for Disease Control, Atlanta, GA, USA) and SPSS 10.0 for Windows (SPSS Inc., 1989-1999).
Results
Febrile episodes
A total of 120 patients (96%) developed fever while neutropenic at a median time of onset of 4 days from the transplant. Clinical or microbiological documentation of infection was achieved in 70 patients (58%): there were 36 bacteremias (30%), 13 microbiologically documented infections without bacteremia (11%) and 21 clinically documented infections (17%). Among the bacteremic episodes, 23 were caused by Gram-positive, 12 by Gramnegative, and one by Gram-positive and Gram-negative bacteria. Coagulase-negative Staphylococcus (nine episodes) and Staphylococcus aureus (six episodes) were the most frequent Gram-positive bacteria, and Klebsiella sp. (four episodes), Enterobacter sp. and Escherichia coli (three episodes each) predominated among the Gram-negative bacteria. Two patients developed candidemia, and eight patients presented fungemia because of Exophiala jeanselmei, during an outbreak at our hospital. 12 In all, 75 patients responded to the empirical antibiotic therapy. A new fever occurred in 36 patients (30% of patients with fever), at a median of 13 days from transplant (range 5-28). A total of 24 patients (67%) had no clinical or microbiological documentation of infection of the secondary febrile episode, nine had a microbiological documentation of fever (fungemia due to E. jeanselmei in three patients, bacteremia due to coagulase-negative Staphylococcus in two, bacteremia due to Klebsiella pneumoniae, Enterobacter cloacae and Acinetobacter calcoaceticus in one each, and urinary infection due to E. coli in one patient), and two patients had clinically documented infection (tunnel infection and cellulitis).
Diagnostic criteria for the ES
Nine patients (7%) presented a noninfectious fever plus skin rash in the early periengraftment period. In three of these patients skin biopsy was performed, and changes consistent with a diagnosis of autologous graft-versus-host disease were present in all. These nine patients were compared with the other 116 patients for the presence of pulmonary infiltrates, neurological manifestations, weight gain, diarrhea, hypoalbuminemia and jaundice, all appearing in the periengraftment period (Table 1) . Pulmonary infiltrates (odds ratio 13.25), weight gain (odds ratio 9.60) and diarrhea (odds ratio 7.81) were significantly more frequent in patients with fever and skin rash. These variables plus hypoalbuminemia (P ¼ 0.08) were entered in a logistic regression analysis. After multivariate analysis, pulmonary infiltrates (P ¼ 0.009, odds ratio 11.61, 95% confidence interval 1.84-73.29) and diarrhea (P ¼ 0.02, odds ratio 9.69, 95% confidence interval 1.52-61.82) remained significant. Therefore, the final diagnostic criteria for the ES were noninfectious fever plus any of the following: skin rash, pulmonary infiltrates or diarrhea. With these criteria, the incidence of the syndrome was 20% (25/125 patients).
Risk factors and outcome of patients with the ES (Tables 2 and 3)
Patients with the ES were older than patients who did not develop the syndrome (P ¼ 0.02), were more likely to have received a transplant from peripheral blood stem cells (P ¼ 0.04), and to have a diagnosis other than Hodgkin's disease (P ¼ 0.008). In addition, there was a trend for higher risk of the ES in patients with multiple myeloma (P ¼ 0.06) and breast cancer (P ¼ 0.09). By multivariate analysis, the single variable significantly associated with the ES was a diagnosis other than Hodgkin's disease (P ¼ 0.02, odds ratio 6.17, 95% confidence interval 1.38-27.78).
Patients with the ES received empirical antifungal therapy more frequently than patients without the syndrome (40 vs 19%, P ¼ 0.03). The use of empirical antifungal therapy was reduced in recent years: until 1998, amphotericin B was used in 35% of patients compared to 13% between 1999 and 2001 (P ¼ 0.002). Patients with the ES had a longer duration of hospitalization (P ¼ 0.0007), with a trend for a longer duration of antibiotic use (P ¼ 0.07) and more platelet transfusions (P ¼ 0.09) compared to patients without the syndrome. The death rates of patients with and without the ES were 16 and 5%, respectively (P ¼ 0.08). Of the 25 patients with ES, 11 (44%) received corticosteroids (methylprednisolone at a dose of 1-2 mg/kg daily). Nine of these 11 patients responded to treatment and two patients died. Among the 14 patients who did not receive corticosteroids, 12 survived and two died (P ¼ 0.41). The death was attributed to the ES in two cases.
Discussion
ES is a recently described entity with many clinical findings but no uniform diagnostic criteria. This has led to a diversity of information regarding the incidence and risk factors. A proposal for a uniform definition of ES that considers major and minor criteria has been recently published by Spitzer, 1 but it was based on the judgment of the author as to which of the various clinical manifestations reported had major or minor importance. Our strategy to construct the definition of the ES was to select the two most frequent and characteristic findings of the syndrome, fever and skin rash, and to evaluate the frequency of the other clinical findings in patients with and without fever and skin rash. We performed univariate analysis, and in order to control for the possibility of interaction between these variables, we performed a multivariate analysis. Using this strategy, pulmonary infiltrates and diarrhea were selected, and the diagnostic criteria were fever accompanied by any of the following: cutaneous rash, pulmonary infiltrates and diarrhea. Interestingly, three of our four criteria are the major criteria used in the proposed diagnostic criteria published recently. 1 The incidence of the ES was 20%, a value intermediate between the low incidence found when strict criteria were used, 4,5 and the high incidence observed in studies that used broader criteria. 6, 7 If we used the criteria proposed by Spitzer, the incidence in our series would be 11%. Steroids have been used to treat the ES with success, 6 but patients with complications like multiple organ failure and respira- Table 1 Clinical characteristics suggestive of the ES in patients with and without fever and skin rash
Fever + skin rash P-value Odds ratio (95% CI) Yes n = 9 (%) No n = 116 (%) 95% CI = 95% confidence interval.
Engraftment syndrome and diagnostic criteria A Maiolino et al tory failure are expected to have a worse prognosis. Therefore, if we choose a strict criterion we lose sensitivity, and this may delay the initiation of treatment. On the contrary, using a broad criterion patients may be overtreated. Risk factors for the ES have been identified in many studies, and include the underlying disease (breast cancer), 4, 7, 13 gender (female), 4 type of chemotherapeutic agent used in the conditioning regimen (etoposide, 2
), the number of cycles of previous chemotherapy, 7 previous radiotherapy, 2 number of mononuclear 4 or CD34+ cells 5 infused, peripheral blood as the source of stem cells, 4 use of G-CSF, 4 faster engraftment, 4,5 previous bacteremia or pneumonia 2 and use of amphotericin B. 2 Besides the limitations regarding different diagnostic criteria among these studies, none of them performed multivariate analysis. In the present study, we identified risk factors by univariate and multivariate analyses. In our univariate analysis, some of the factors identified previously were significant: transplant from peripheral blood stem cells and breast cancer (P ¼ 0.09). In addition, the ES occurred less frequently in patients with Hodgkin's, and by multivariate analysis this was the single variable that remained significant.
In the present study, the use of empirical amphotericin B was more frequent in patients with the ES. This variable was identified as a risk factor in another study, and explained by a possible leukocyte activation mediated by amphotericin B, with consequent respiratory failure. 2 However, the association between pulmonary reactions to amphotericin B and leukocyte migration has been questioned. 14 Our interpretation is that amphotericin B use seems to be a surrogate marker for the syndrome instead of risk factor, since the time of occurrence of the ES coincides This argument may be further illustrated by our observation of a reduction in the use of amphotericin B in recent years without a reduction in the incidence of the syndrome. Since we have become more aware of the ES, patients with a new fever and clinical manifestations of the syndrome did not receive amphotericin B.
The presence of the ES had a negative impact on the duration of hospitalization and use of platelets. Platelet transfusion refractoriness has been described in the ES. 7 In addition, although not statistically significant, there was a trend for higher mortality in patients with the ES. The outcome of the ES was not different between patients who did or did not receive corticosteroids. Owing to the retrospective nature of the study and the lack of standard criteria for starting corticosteroids, we cannot draw firm conclusions about the impact of the use of corticosteroids on the outcome.
Our study suffers from the limitations of its retrospective nature. Nevertheless, if confirmed by carefully conducted prospective clinical studies, our findings may have implications for the clinical management of autologous HSCT recipients. Once diagnostic criteria have been defined in a systematic fashion, these criteria may be applied prospectively in order to further determine the incidence and risk factors. In addition, patients may take advantage of an early diagnosis of the syndrome, with a reduction in the unnecessary use of antimicrobial agents. Likewise, prospective studies may further explore the impact of early initiation of corticosteroids on the outcome of the ES.
